Navigation Links
Purdue startup hopes to change the way we test cancer drugs

WEST LAFAYETTE, Ind. - A Purdue University scientist's nanopolymer would make it easier and cheaper for drug developers to test the effectiveness of a widely used class of cancer inhibitors.

W. Andy Tao, an associate professor of biochemistry analytical chemistry and a member of the Purdue Center for Cancer Research team, created the Purdue-patented pIMAGO nanopolymer that can be used to determine whether cancer drugs have been effective against biochemical processes that can lead to cancer cell formation. The nanopolymers would attach themselves to target proteins that would later be detected by a relatively simple laboratory procedure called chemiluminescence.

Tymora Analytical, a company Tao started in the Purdue Research Park, will manufacture the pIMAGO nanopolymers. The 'p' stands for phosphor, and the IMAGO comes from the Greek word for image.

Tao's pIMAGO nanopolymers are coated in titanium ions and would attract and bond with phosphorylated proteins, ones in which a phosphate group has been added to a protein activating an enzyme called kinase. Kinase, when overactive, is known to cause cancer cell formation, and many cancer drugs are aimed at inhibiting kinase activity.

"It is universal. You can detect any kind of phosphorylation in a protein," said Tao, whose findings were reported in the early online version of the journal Analytical Chemistry. "It is also cheaper and would be more widely available."

The nanopolymers would be added to a solution of proteins, a chemical agent to start phosphorylation and a drug to inhibit kinase activity. Phosphorylated proteins would only be present if the drug is ineffective.

Avidin-HRP - the protein Avidin bound with the enzyme horseradish peroxidase - would be added. Avidin would bind with a vitamin B acid called biotin that is also on the nanopolymers' surfaces. A chemical called a substrate, added later, would cause a reaction with HRP, causing the solution to change color.

A lightly colored solution would mean there had been little kinase activity and few phosphorylated proteins and that the drug was effective. A darker solution would signal more kinase activity and a less effective drug.

"This could have a lot of applications in pharmaceuticals for drug discovery," Tao said.

Screening kinase inhibitors using antibodies can be cost-prohibitive for many laboratories because antibodies are in short supply and aren't available for many types of cells. Radioisotope tests are highly regulated and possibly dangerous because of radiation involved.

"We want to develop this as a commercial application to replace radioisotopes and antibodies as a universal method for screening kinase inhibitors," Tao said.


Contact: Brian Wallheimer
Purdue University

Related biology news :

1. Purdue researcher invents molecule that stops SARS
2. Purdue study suggests warmer temperatures could lead to a boom in corn pests
3. Purdue study finds dairy better for bones than calcium carbonate
4. Protein can help cells or cause cancer, Purdue researcher finds
5. NASA, Purdue study offers recipe for global warming-free industrial materials
6. Purdue team creates engineered organ model for breast cancer research
7. Texas invests record $3.5 million in startup cofounded by UTs Mauro Ferrari
8. Iowa State chemist synthesizes carbohydrates, launches startup company
9. Case Western Reserve University grants option to startup Thermalin Diabetes Inc.
10. Startup joins UCLA tech incubator to develop technologies for drug discovery, screening
11. Wireless sensor startup wins UC San Diego $80K Entrepreneur Challenge
Post Your Comments:
Related Image:
Purdue startup hopes to change the way we test cancer drugs
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or "the ... results for the quarter ended September 30, 2015. ... dollars and presented under International Financial Reporting Standards ... ," said Andrew Rae , President & ... are not only value enriching for this clinical ...
(Date:11/24/2015)... 2015  Clintrax Global, Inc., a worldwide provider of clinical research ... announced that the company has set a new quarterly earnings record ... quarter growth posted for Q3 of 2014 to Q3 of 2015. ... Mexico , with the establishment of an Asia-Pacific ... United Kingdom and Mexico ...
(Date:11/24/2015)... 2015 SHPG ) announced today that ... Jaffray 27 th Annual Healthcare Conference in New ... 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
(Date:11/24/2015)... , Nov. 24, 2015  Twist Bioscience, ... that Emily Leproust, Ph.D., Twist Bioscience chief executive ... Healthcare Conference on December 1, 2015 at 3:10 ... in New York City. --> ... . Twist Bioscience is on Twitter. Sign ...
Breaking Biology Technology: